Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24820026 | 0.85 | DPP4 (0.41) | DPP4DPP7USP19SMYD3 | |
| SCHEMBL24368972 | 0.81 | DPP4 (0.44) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL2636048 | 0.81 | DPP4 (0.44) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL24368970 | 0.81 | DPP4 (0.44) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL14843725 | 0.81 | DPP4 (0.44) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL22034571 | 0.81 | DPP4 (0.44) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL24369514 | 0.79 | DPP4 (0.46) | DPP4DPP7USP19TDP1SMYD3 | |
| SCHEMBL787532 | 0.79 | DPP4 (0.46) | DPP4DPP7USP19SMYD3PIK3CD | |
| SCHEMBL24369511 | 0.79 | DPP4 (0.46) | DPP4DPP7USP19TDP1SMYD3 | |
| Hydrochloric Acid SCHEMBL15709523 | 0.78 | DPP4 (0.45) | DPP4DPP7USP19SMYD3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | claimed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | claimed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | claimed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | DPP4 1638/4885DPP7 2630/4885USP19 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.